Discover investment opportunities in Stocks Under 5 Cents using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks Under 5 Cents using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks Under 5 Cents using our Smart AI Filter.
6 stocks found for "Stocks Under 5 Cents"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.59 | ±100.0% | -0.1 | 0.00% | |||
1.43 | ±75.7% | -0.7 | 0.00% | |||
0.17 | ±100.0% | -0.1 | 0.00% | |||
0.54 | ±100.0% | -0.4 | 0.00% | |||
1.56 | ±100.0% | 0.0 | 0.00% | |||
0.51 | ±100.0% | -0.1 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: Why are stocks priced under 5 cents often considered high-risk investments?
A: Stocks priced under 5 cents, like SYRS and VIRX, are often small-cap or penny stocks. They can exhibit high volatility due to lower liquidity and susceptibility to market manipulation. Generally, these companies may face financial instability, limited operational history, or uncertainty about future profitability.
Q: What sectors do the stocks SYRS and VIRX belong to, and what are the potential opportunities?
A: SYRS operates in the biotechnology sector, targeting unmet medical needs, while VIRX focuses on viral therapies. Potential opportunities include breakthrough innovations or successful clinical trials, which could lead to significant stock price appreciation; however, this also involves high-risk due to regulatory and research uncertainties.
Q: Are stocks like BIOL and CUTR generally impacted by economic cycles?
A: Yes, BIOL, involved in dental technology, and CUTR, in aesthetic systems, might experience demand fluctuations linked to economic cycles. During downturns, discretionary spending on non-essential health and beauty services typically decreases, potentially impacting revenue.
Q: How might investors assess the growth potential of stocks like VINC?
A: Investors may examine factors such as VINC's market position, product innovation, and financial reports. Analyzing recent performance, industry trends, and any news releases is also crucial for understanding growth prospects.
Q: What should investors look out for when investing in a stock like ZPTA?
A: Investors should consider ZPTA's financial health, competitive position in its sector, and any strategic initiatives. Examining its past performance, management team, and any market catalysts can help assess potential risks and rewards.
Q: Do stocks such as BIOL offer any advantages in terms of technology and innovation?
A: BIOL specializes in dental lasers and advanced surgery tools, offering potential technological advantages. The company may benefit from innovations in dental care, but success depends on adoption rates and continued product development.
On Friday, Virpax Pharmaceuticals, Inc. VRPX completed the full study following the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and Development Agreement (CRADA).
Read moreWe are initiating coverage of Adaptimmune Therapeutics plc ADAP with a 12-month price target of $3.00, translating into sizeable upside from the stock's current price. Adaptimmune designs, develops, manufactures, and delivers innovative cell therapies via the company's unique T-cell receptor (TCR) platform to treat cancers across multiple solid tumor types.
Read more